Ambu on EU bronchoscope approval: Makes us the most wide-ranging and dominant player on the market

Wednesday's CE mark authorization for Ambu's latest bronchoscope and attached sampling system will have a positive effect on the company's total endoscopy sales, and the green light itself shows that they are the most innovative player, the firm says.

Photo: Ambu/PR

Competition has been heating up on the market for pulmonary endoscopes, also called bronchoscopes, where Ambu's product Ascope has been very successful.

Boston Scientific, Pentax, Olympus and Verathon have all thrown their hats into the ring, and Chinese copycats are emerging.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs